Elemento Lab

Publications

Found 306 results
Filters: First Letter Of Last Name is B  [Clear All Filters]
2021
Woo XYi, Giordano J, Srivastava A, Zhao Z-M, Lloyd MW, de Bruijn R, Suh Y-S, Patidar R, Chen L, Scherer S et al..  2021.  Author Correction: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts.. Nat Genet. 53(5):761.
Woo XYi, Giordano J, Srivastava A, Zhao Z-M, Lloyd MW, de Bruijn R, Suh Y-S, Patidar R, Chen L, Scherer S et al..  2021.  Author Correction: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts.. Nat Genet. 53(5):761.
Woo XYi, Giordano J, Srivastava A, Zhao Z-M, Lloyd MW, de Bruijn R, Suh Y-S, Patidar R, Chen L, Scherer S et al..  2021.  Author Correction: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts.. Nat Genet. 53(5):761.
Woo XYi, Giordano J, Srivastava A, Zhao Z-M, Lloyd MW, de Bruijn R, Suh Y-S, Patidar R, Chen L, Scherer S et al..  2021.  Author Correction: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts.. Nat Genet. 53(5):761.
Woo XYi, Giordano J, Srivastava A, Zhao Z-M, Lloyd MW, de Bruijn R, Suh Y-S, Patidar R, Chen L, Scherer S et al..  2021.  Author Correction: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts.. Nat Genet. 53(5):761.
Woo XYi, Giordano J, Srivastava A, Zhao Z-M, Lloyd MW, de Bruijn R, Suh Y-S, Patidar R, Chen L, Scherer S et al..  2021.  Author Correction: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts.. Nat Genet. 53(5):761.
Croker JA, Patel R, Campbell KS, Barton-Baxter M, Wallet S, Firestein GS, Kimberly RP, Elemento O.  2021.  Building biorepositories in the midst of a pandemic.. J Clin Transl Sci. 5(1):e92.
Napoli S, Cascione L, Rinaldi A, Spriano F, Guidetti F, Zhang F, Cacciapuoti MTeresa, Mensah AAdjeiwaa, Sartori G, Munz N et al..  2021.  Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B cell lymphoma.. Haematologica.
Napoli S, Cascione L, Rinaldi A, Spriano F, Guidetti F, Zhang F, Cacciapuoti MTeresa, Mensah AAdjeiwaa, Sartori G, Munz N et al..  2021.  Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B cell lymphoma.. Haematologica.
Bruno NE, Nwachukwu JC, Srinivasan S, Nettles CC, Izard T, Jin Z, Nowak J, Cameron MD, Boregowda SV, Phinney DG et al..  2021.  Chemical systems biology reveals mechanisms of glucocorticoid receptor signaling.. Nat Chem Biol. 17(3):307-316.
Bruno NE, Nwachukwu JC, Srinivasan S, Nettles CC, Izard T, Jin Z, Nowak J, Cameron MD, Boregowda SV, Phinney DG et al..  2021.  Chemical systems biology reveals mechanisms of glucocorticoid receptor signaling.. Nat Chem Biol. 17(3):307-316.
Jobanputra V, Wrzeszczynski KO, Buttner R, Caldas C, Cuppen E, Grimmond S, Haferlach T, Mullighan C, Schuh A, Elemento O.  2021.  Clinical interpretation of whole-genome and whole-transcriptome sequencing for precision oncology.. Semin Cancer Biol.
Rosenquist R, Cuppen E, Buettner R, Caldas C, Dreau H, Elemento O, Frederix G, Grimmond S, Haferlach T, Jobanputra V et al..  2021.  Clinical utility of whole-genome sequencing in precision oncology.. Semin Cancer Biol.
Khosravi P, Lysandrou M, Eljalby M, Li Q, Kazemi E, Zisimopoulos P, Sigaras A, Brendel M, Barnes J, Ricketts C et al..  2021.  A Deep Learning Approach to Diagnostic Classification of Prostate Cancer Using Pathology-Radiology Fusion.. J Magn Reson Imaging. 54(2):462-471.
Khosravi P, Lysandrou M, Eljalby M, Li Q, Kazemi E, Zisimopoulos P, Sigaras A, Brendel M, Barnes J, Ricketts C et al..  2021.  A Deep Learning Approach to Diagnostic Classification of Prostate Cancer Using Pathology-Radiology Fusion.. J Magn Reson Imaging. 54(2):462-471.
Xu Z, Verma A, Naveed U, Bakhoum SF, Khosravi P, Elemento O.  2021.  Deep learning predicts chromosomal instability from histopathology images.. iScience. 24(5):102394.
Pan H, Renaud L, Chaligne R, Bloehdorn J, Tausch E, Mertens D, Fink AMaria, Fischer K, Zhang C, Betel D et al..  2021.  Discovery of candidate DNA methylation cancer driver genes.. Cancer Discov.
Pan H, Renaud L, Chaligne R, Bloehdorn J, Tausch E, Mertens D, Fink AMaria, Fischer K, Zhang C, Betel D et al..  2021.  Discovery of candidate DNA methylation cancer driver genes.. Cancer Discov.
Montrose DC, Saha S, Foronda M, McNally EM, Chen J, Zhou XKathy, Ha T, Krumsiek J, Buyukozkan M, Verma A et al..  2021.  Exogenous and Endogenous Sources of Serine Contribute to Colon Cancer Metabolism, Growth, and Resistance to 5-Fluorouracil.. Cancer Res. 81(9):2275-2288.
Yusufova N, Kloetgen A, Teater M, Osunsade A, Camarillo JM, Chin CR, Doane AS, Venters BJ, Portillo-Ledesma S, Conway J et al..  2021.  Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture.. Nature. 589(7841):299-305.
Beg S, Bareja R, Ohara K, Eng KWha, Wilkes DC, Pisapia DJ, Zoughbi WAl, Kudman S, Zhang W, Rao R et al..  2021.  Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology.. Transl Oncol. 14(1):100944.
Beg S, Bareja R, Ohara K, Eng KWha, Wilkes DC, Pisapia DJ, Zoughbi WAl, Kudman S, Zhang W, Rao R et al..  2021.  Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology.. Transl Oncol. 14(1):100944.
Beg S, Bareja R, Ohara K, Eng KWha, Wilkes DC, Pisapia DJ, Zoughbi WAl, Kudman S, Zhang W, Rao R et al..  2021.  Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology.. Transl Oncol. 14(1):100944.
Altorki NK, McGraw TE, Borczuk AC, Saxena A, Port JL, Stiles BM, Lee BE, Sanfilippo NJ, Scheff RJ, Pua BB et al..  2021.  Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.. Lancet Oncol. 22(6):824-835.
Altorki NK, McGraw TE, Borczuk AC, Saxena A, Port JL, Stiles BM, Lee BE, Sanfilippo NJ, Scheff RJ, Pua BB et al..  2021.  Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.. Lancet Oncol. 22(6):824-835.